上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Nelarabine (Synonyms: 奈拉滨; 506U78; GW 506U78; Nelzarabine) 纯度: 99.88%
Nelarabine (Arranon, 506U78)是嘌呤核苷酸类似物,为DNA合成抑制剂,对肿瘤细胞的IC50为0.067-2.15 μM,可作用于T细胞急性淋巴细胞白血病。
Nelarabine Chemical Structure
CAS No. : 121032-29-9
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
10 mM * 1 mL in DMSO | ¥1377 | In-stock | |
5 mg | ¥1252 | In-stock | |
10 mg | ¥2358 | In-stock | |
50 mg | ¥7149 | In-stock | |
100 mg | ¥10114 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
Nelarabine 相关产品
•相关化合物库:
- Drug Repurposing Compound Library Plus
- FDA-Approved Drug Library Plus
- FDA-Approved Drug Library Mini
- Bioactive Compound Library Plus
- Apoptosis Compound Library
- Cell Cycle/DNA Damage Compound Library
- FDA-Approved Drug Library
- Anti-Cancer Compound Library
- Anti-Aging Compound Library
- Drug Repurposing Compound Library
- Reprogramming Compound Library
- Nucleotide Compound Library
- Anti-COVID-19 Compound Library
- FDA Approved & Pharmacopeial Drug Library
- Anti-Lung Cancer Compound Library
- Drug-Induced Liver Injury (DILI) Compound Library
- Anti-Blood Cancer Compound Library
- Anti-Cancer Metabolism Compound Library
- Rare Diseases Drug Library
生物活性 |
Nelarabine (Arranon, 506U78) is a purine nucleoside analog and DNA synthesis inhibitor with IC50 from 0.067-2.15 μM in tumor cells. Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. IC50 Value: 0.44 uM (HSB2 cell lines); 1.24 μM(ALL-SIL cell lines); 2.15 μM(JURKAT cell lines); 0.067 uM (PER-255 cell lines) [1] Target: Nucleoside antimetabolite/analog in vitro: The IC50 of Nelarabine is 25-fold and 113-fold higher than ARAC in T- and B-lineage, respectively. T-ALL cells are eightfold more sensitive to Nelarabine than B-lineage but there is considerable overlap. The efficacy of NEL in T-lineage and B-lineage cell lines is 25-fold and 113-fold less than ARAC, respectively [1]. in vivo: The median age was 34 years (range, 16-66 years); 32 (82%) patients were male. The rate of complete remission was 31% (95% confidence interval [CI], 17%, 48%) and the overall response rate was 41% (95% CI, 26%, 58%). The principal toxicity was grade 3 or 4 neutropenia and thrombocytopenia, occurring in 37% and 26% of patients, respectively [2]. Nelarabine has activity in T-cell malignancies, as evaluated in 2 Phase I and 5 Phase II studies. It received accelerated approval from the FDA based on the resuits of 2 Phase II trials, one in pediatric patients (PGAA 2001) and the other in adults (CALGB 19801) Toxicity: The principal toxicity was grade 3 or 4 neutropenia and thrombocytopenia, occurring in 37% and 26% of patients, respectively [2]. Clinical trial: Drug Use Investigation for Arranon G (Nelarabine) Injection 250 mg. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Clinical Trial |
|
||||||||||||||||
分子量 |
297.27 |
||||||||||||||||
Formula |
C11H15N5O5 |
||||||||||||||||
CAS 号 |
121032-29-9 |
||||||||||||||||
中文名称 |
奈拉滨 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 100 mg/mL (336.39 mM; Need ultrasonic) H2O : 10 mg/mL (33.64 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务